NON-ALCOHOLIC STEATOHEPATITIS

This early-stage trial tested a new oral drug called J2H-1702 in 100 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a type of liver disease. The study was completed and used a placebo for compa…

This study tested a single dose of the experimental drug GSK4532990 in 61 adults with NASH, a type of fatty liver disease. Researchers measured how the drug moves through the body and affects liver proteins, while also checking for safety. The goal is to see if the drug can help …

This study tested a new drug, ARO-HSD, in 50 healthy volunteers and people with NASH (a serious fatty liver disease). The goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo injection. The trial is now complete, …

This study tested whether combining a new liver drug (NNC0194-0499) with semaglutide (a diabetes/weight-loss drug) can reduce liver scarring in people with NASH, a serious fatty liver disease. About 700 adults received weekly injections of either the drug combo, a different combo…

This study tested an oral drug called MGL-3196 in 125 adults with NASH, a serious liver disease. The main goal was to see if the drug could reduce liver fat measured by MRI after 12 weeks, compared to a placebo. Results suggest the drug may help control the disease, but long-term…

This early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and …

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly…

This study tested a new ultrasound feature that measures liver fat in children with or at risk for fatty liver disease. Researchers compared the ultrasound results to MRI scans, which are the current standard. The goal was to see if the simpler, faster ultrasound could give relia…

This study looked at how consistent a special MRI scan called LiverMultiScan is at measuring liver fat, iron, and scarring. 61 adults with different liver diseases were scanned multiple times on the same machine and on different machines. The goal was to see if the scan gives the…

This early-stage trial tested the safety and tolerability of a single dose of J2H-1702 in 16 healthy women. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers measured how the body processes the drug and its effects, but t…

This early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather e…

This study tested a new ultrasound feature that measures liver fat and compared it to the standard MRI method. About 60 adults with or at risk for fatty liver disease had two ultrasounds and one MRI. The goal was to see if the ultrasound could accurately estimate liver fat, which…

This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with …

This study tested whether a pop-up alert in the electronic medical record could help doctors remember to refer patients with fatty liver disease (NASH) to a liver specialist. Thirty doctors from internal medicine, family medicine, and endocrinology took part. The goal was to see …

This study examined medical records of 263 adults with NASH to see how factors like age, other health problems, and medications relate to the severity of liver scarring. The goal was to identify which patients are at higher risk for advanced fibrosis. The findings may help doctor…